Stability of Gabapentin in SyrSpend SF
Author(s): Sorenson Bridget, Voudrie Mark A II, Gehrig Dan
Issue: Jul/Aug 2012 - Volume 16, Number 4
View All Articles in Issue
Page(s): 347-349
Download in electronic PDF format for $75
Abstract: Gabapentin is used with other medications to control and prevent seizures. It is also used to treat neuropathic pain following surgery due to shingles. Gabapentin comes in many different forms, including capsules, tablets, and oral solutions. Some patients, however, cannot use oral solutions containing alcohol or sorbitol. The objective of this study was to determine the stability of gabapentin in SyrSpend SF, a suspending agent that does not contain either sorbitol or alcohol. The studied samples were compounded into a 50-mg/mL suspension and stored in low actinic bottles at room temperature and refrigerated conditions. Samples were assayed at each time point out to 90 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced-degradation studies. The samples remained within 90% to 110% of the initial concentration throughout the course of the study. Based on data collected, the beyond-use date of this product is at least 90 days when refrigerated or stored at room temperature and protected from light. Based on the final potency data at day 90, the beyond-use date may be longer, but 90 days was the limit of this study.
Related Keywords:
gabapentin, anticonvulsant, antiepileptic agent, seizure disorders, oral suspension, SyrSpend, stability
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Gabapentin in SyrSpend SF
Sorenson Bridget, Voudrie Mark A II, Gehrig Dan
|
Jul/Aug 2012
Pg. 347-349
|
Gabapentin 50-mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 486
|
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
|
Jul/Aug 2020
Pg. 327-336
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul
|
Sep/Oct 2015
Pg. 420-427
|
Gabapentin 100 mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
May/Jun 2018
Pg. 235
|
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 344-346
|
Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution)
Voudrie Mark A II, Allen D Brett
|
Jan/Feb 2010
Pg. 82-85
|
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System
Vu Nicole T, Aloumanis Vasileios, Ben Michel J, Kupiec Thomas C, Patterson Evelyn K, Radke Joshua, Erickson Martin A III, Schneider Gary
|
Nov/Dec 2008
Pg. 558-564
|
Lamotrigine 1-mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 148
|
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
|
Mar/Apr 2016
Pg. 167-174
|
Carbamazepine 25-mg/mL in SyrSPend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 409
|
Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Voudrie Mark A, Alexander Bridget, Allen D Brett
|
May/Jun 2011
Pg. 255-258
|
Stability of Captopril in SyrSPend SF
Geiger Christine M, Sorenson Bridget, Whaley Paul A
|
Jul/Aug 2013
Pg. 336-338
|
Stability of Ursodiol in SyrSpend SF Cherry Flavored
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 510-512
|
Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
|
Nov/Dec 2012
Pg. 513-515
|
Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 412
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Gabapentin 100-mg/mL Oral Liquid
Allen Loyd V Jr
|
Nov/Dec 2006
Pg. 456
|
Metronidazole Benzoate 70 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 320
|
Return to Top |